Retinal Disease Therapeutics Market
Retinal Disease Therapeutics Market Forecasts to 2030 - Global Analysis By Type (Macular Degeneration, Diabetic Eye Disease, Retinal Detachment, Retinoblastoma, Macular Pucker, Macular Hole, Floaters and Other Types), Disorder Type (Genetic and Age Related, Treatment Technique (Laser, Freezing, Implanting, Indenting, Pneumatic Retinopexy, Scleral Buckling and Vitrectomy), Dosage Form, Route of Administration, Distribution Channel, End User and by Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $13.99 BN |
|
Projected Year Value (2030) |
US $29.60 BN |
|
CAGR (2023 - 2030) |
11.3% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Europe |
According to Stratistics MRC, the Global Retinal Disease Therapeutics Market is accounted for $13.99 billion in 2023 and is expected to reach $29.60 billion by 2030 growing at a CAGR of 11.3% during the forecast period. A collection of disorders known as retinal diseases impact the retina, the light-sensitive tissue found at the rear of the eye. These illnesses have the potential to impair the retina's normal function, which could result in blindness or visual impairment. Moreover, the goal of therapies for retinal diseases is to control and treat these conditions in order to maintain or enhance a patient's vision. Depending on the exact ailment and its severity, different treatment modalities may be used, such as medication, laser therapy, surgery, and implantable devices.
According to the World Vision Report released by the World Health Organisation (WHO), nearly 2.2 billion people suffer from vision impairment worldwide, of which approximately 60 million people are blind.
Market Dynamics:
Driver:
Expanding diabetes incidence
Retinal disease therapies are seeing significant growth due to the rise in diabetes cases worldwide, which is being caused by dietary and lifestyle modifications. Moreover, the increasing number of diabetes cases globally is directly correlated with an increased demand for therapeutics addressing diabetic retinal complications, as diabetes is a major risk factor for diabetic retinopathy, a condition that frequently results in vision impairment.
Restraint:
Lack of compliance with treatment
Frequent intravitreal injections are one of the ongoing, occasionally invasive treatments required for certain retinal diseases. Inconsistent adherence to these treatment plans may result from patient resistance brought on by discomfort, fear, or other issues. Additionally, poor adherence reduces the efficacy of therapeutic interventions and may jeopardize patients' long-term results. Improving treatment convenience and addressing patient concerns are essential for raising adherence rates.
Opportunity:
Developments in customized medicine
Personalized medicine in retinal disease therapeutics is made possible by the continuous integration of genomic and molecular data into clinical practice. Targeted therapies can be developed according to each patient's unique genetic composition thanks to thorough genetic profiling and biomarker analysis. Furthermore, precision medicine may advance significantly with this strategy, which aims to minimize side effects and optimize treatment efficacy.
Threat:
Affordability and economic barriers
The availability of treatments for retinal diseases may be severely hampered by economic inequality and high treatment expenses. In addition to restricting patient access, financial worries can put pressure on healthcare systems and make it more difficult to provide complete care. Recessions and other economic downturns have the potential to worsen these obstacles and put the fair distribution of cutting-edge retinal treatments in jeopardy.
Covid-19 Impact:
The market for treatments for retinal diseases has been greatly impacted by the COVID-19 pandemic. Diagnosis and treatment of retinal diseases have been delayed due to disruptions in healthcare systems, redirection of resources to pandemic response, and restrictions on patient access to routine care. Interruptions in clinical trials have impeded the development of new treatments. Furthermore, changes in healthcare priorities and economic uncertainty have affected market dynamics, potentially having long-term effects on funding for research and the development of treatments for retinal diseases. The pandemic has increased the use of telemedicine solutions in the treatment of retinal diseases and highlighted the significance of robust healthcare systems.
The Macular Degeneration segment is expected to be the largest during the forecast period
In the market for treatments for retinal diseases, the macular degeneration segment holds the largest share. Among older adults, macular degeneration—more specifically, age-related macular degeneration, or AMD—is a common and primary cause of vision loss. Moreover, the aging population on a global scale is driving the prominence of this segment. The macula, the core portion of the retina, is impacted by AMD, which can cause vision distortion or blurriness and, in extreme situations, central vision loss. Anti-VEGF medications and other targeted treatments meant to impede the advancement of the condition are available on the market for macular degeneration therapeutics.
The Home Healthcare segment is expected to have the highest CAGR during the forecast period
In the market, the Home Healthcare segment is growing at the highest CAGR. The need for patient-centered care, the aging population, and technological advancements that enable more complex treatments to be administered at home have all contributed to the rise in popularity of home healthcare. Additionally, a vast array of medical and non-medical treatments is included in home healthcare services, such as medication administration, chronic condition monitoring, and rehabilitation therapy delivered to patients in the comfort of their own homes.
Region with largest share:
In the global retinal disease therapeutics market, North America is expected to hold the largest share. The region's large and aging population, which makes it vulnerable to retinal diseases, its sophisticated healthcare infrastructure, and a thriving ecosystem of ophthalmic treatment-focused research and development activities all, contribute to its leadership. Major pharmaceutical companies, academic research centers, and cutting-edge healthcare facilities are some of the factors that consistently make North America a leader in the retinal disease therapeutics industry. A proactive regulatory environment that encourages innovation and speeds up the approval process for new treatments is another advantage that the region enjoys.
Region with highest CAGR:
In the market for treatments for retinal diseases, the Europe region is anticipated to have the highest CAGR. Benefits to the area include an established healthcare system, a high rate of age-related retinal diseases, and the early adoption of cutting-edge therapies. The United Kingdom, Germany, and France are among the European nations that place a high priority on ophthalmology research and development, which promotes improvements in the treatments for retinal diseases. Moreover, the notable growth in the region is also attributed to favourable regulatory frameworks and growing partnerships between pharmaceutical companies and academic institutions.
Key players in the market
Some of the key players in Retinal Disease Therapeutics market include Santen Pharmaceutical Co. Ltd., AbbVie Inc., Johnson & Johnson Services, Inc, Bayer AG, Regeneron Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Roche Holding AG, Genentech, Inc., Alcon Inc., Novartis AG, F. Hoffmann-La Roche AG, Senju Pharmaceutical Co., Ltd. , Bausch Health Companies Inc., Allergan plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Spark Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Clearside Biomedical, Inc. and Kubota Pharmaceutical Holdings Co., Ltd.
Key Developments:
In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company’s “Library of Libraries,” a collection of synthetic antibody libraries that harnesses innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery.
In July 2023, Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an out-licensing agreement with Visiox Pharmaceuticals, Inc. (hereafter Visiox) on the rights to product manufacturing, commercialization, and sales of OMLONTI®, an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
In February 2023, AbbVie and Capsida Biotherapeutics Inc. announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021.
Types Covered:
• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters
• Other Types
Disorder Types Covered:
• Genetic
• Age Related
Treatment Techniques Covered:
• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy
Dosage Forms Covered:
• Gels
• Eye solutions
• Capsules & Tablets
• Eye Drops
• Ointments
• Other Dosage Forms
Route of Administrations Covered:
• Oral
• Topical
• Intravitreal
Distribution Channels Covered:
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Direct Tender
• Other Distribution Channels
End Users Covered:
• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Retinal Disease Therapeutics Market, By Type
5.1 Introduction
5.2 Macular Degeneration
5.3 Diabetic Eye Disease
5.4 Retinal Detachment
5.5 Retinoblastoma
5.6 Macular Pucker
5.7 Macular Hole
5.8 Floaters
5.9 Other Types
6 Global Retinal Disease Therapeutics Market, By Disorder Type
6.1 Introduction
6.2 Genetic
6.3 Age Related
7 Global Retinal Disease Therapeutics Market, By Treatment Technique
7.1 Introduction
7.2 Laser
7.3 Freezing
7.4 Implanting
7.5 Indenting
7.6 Pneumatic Retinopexy
7.7 Scleral Buckling
7.8 Vitrectomy
8 Global Retinal Disease Therapeutics Market, By Dosage Form
8.1 Introduction
8.2 Gels
8.3 Eye solutions
8.4 Capsules & Tablets
8.5 Eye Drops
8.6 Ointments
8.7 Other Dosage Forms
9 Global Retinal Disease Therapeutics Market, By Route of Administration
9.1 Introduction
9.2 Oral
9.3 Topical
9.4 Intravitreal
10 Global Retinal Disease Therapeutics Market, By Distribution Channel
10.1 Introduction
10.2 Hospital Pharmacy
10.3 Online Pharmacy
10.4 Retail Pharmacy
10.5 Direct Tender
10.6 Other Distribution Channels
11 Global Retinal Disease Therapeutics Market, By End User
11.1 Introduction
11.2 Hospitals
11.3 Ambulatory Surgical Centers
11.4 Home Healthcare
11.5 Other End Users
12 Global Retinal Disease Therapeutics Market, By Geography
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 New Zealand
12.4.6 South Korea
12.4.7 Rest of Asia Pacific
12.5 South America
12.5.1 Argentina
12.5.2 Brazil
12.5.3 Chile
12.5.4 Rest of South America
12.6 Middle East & Africa
12.6.1 Saudi Arabia
12.6.2 UAE
12.6.3 Qatar
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
13 Key Developments
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.3 New Product Launch
13.4 Expansions
13.5 Other Key Strategies
14 Company Profiling
14.1 Santen Pharmaceutical Co. Ltd.
14.2 AbbVie Inc.
14.3 Johnson & Johnson Services, Inc
14.4 Bayer AG
14.5 Regeneron Pharmaceuticals, Inc.
14.6 Adverum Biotechnologies, Inc.
14.7 Roche Holding AG
14.8 Genentech, Inc.
14.9 Alcon Inc.
14.10 Novartis AG
14.11 F. Hoffmann-La Roche AG
14.12 Senju Pharmaceutical Co., Ltd.
14.13 Bausch Health Companies Inc.
14.14 Allergan plc
14.15 Sun Pharmaceutical Industries Ltd.
14.16 Merck & Co., Inc.
14.17 Spark Therapeutics, Inc.
14.18 Teva Pharmaceutical Industries Ltd.
14.19 Clearside Biomedical, Inc.
14.20 Kubota Pharmaceutical Holdings Co., Ltd.
List of Tables
1 Global Retinal Disease Therapeutics Market Outlook, By Region (2021-2030) ($MN)
2 Global Retinal Disease Therapeutics Market Outlook, By Type (2021-2030) ($MN)
3 Global Retinal Disease Therapeutics Market Outlook, By Macular Degeneration (2021-2030) ($MN)
4 Global Retinal Disease Therapeutics Market Outlook, By Diabetic Eye Disease (2021-2030) ($MN)
5 Global Retinal Disease Therapeutics Market Outlook, By Retinal Detachment (2021-2030) ($MN)
6 Global Retinal Disease Therapeutics Market Outlook, By Retinoblastoma (2021-2030) ($MN)
7 Global Retinal Disease Therapeutics Market Outlook, By Macular Pucker (2021-2030) ($MN)
8 Global Retinal Disease Therapeutics Market Outlook, By Macular Hole (2021-2030) ($MN)
9 Global Retinal Disease Therapeutics Market Outlook, By Floaters (2021-2030) ($MN)
10 Global Retinal Disease Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
11 Global Retinal Disease Therapeutics Market Outlook, By Disorder Type (2021-2030) ($MN)
12 Global Retinal Disease Therapeutics Market Outlook, By Genetic (2021-2030) ($MN)
13 Global Retinal Disease Therapeutics Market Outlook, By Age Related (2021-2030) ($MN)
14 Global Retinal Disease Therapeutics Market Outlook, By Treatment Technique (2021-2030) ($MN)
15 Global Retinal Disease Therapeutics Market Outlook, By Laser (2021-2030) ($MN)
16 Global Retinal Disease Therapeutics Market Outlook, By Freezing (2021-2030) ($MN)
17 Global Retinal Disease Therapeutics Market Outlook, By Implanting (2021-2030) ($MN)
18 Global Retinal Disease Therapeutics Market Outlook, By Indenting (2021-2030) ($MN)
19 Global Retinal Disease Therapeutics Market Outlook, By Pneumatic Retinopexy (2021-2030) ($MN)
20 Global Retinal Disease Therapeutics Market Outlook, By Scleral Buckling (2021-2030) ($MN)
21 Global Retinal Disease Therapeutics Market Outlook, By Vitrectomy (2021-2030) ($MN)
22 Global Retinal Disease Therapeutics Market Outlook, By Dosage Form (2021-2030) ($MN)
23 Global Retinal Disease Therapeutics Market Outlook, By Gels (2021-2030) ($MN)
24 Global Retinal Disease Therapeutics Market Outlook, By Eye solutions (2021-2030) ($MN)
25 Global Retinal Disease Therapeutics Market Outlook, By Capsules & Tablets (2021-2030) ($MN)
26 Global Retinal Disease Therapeutics Market Outlook, By Eye Drops (2021-2030) ($MN)
27 Global Retinal Disease Therapeutics Market Outlook, By Ointments (2021-2030) ($MN)
28 Global Retinal Disease Therapeutics Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
29 Global Retinal Disease Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
30 Global Retinal Disease Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
31 Global Retinal Disease Therapeutics Market Outlook, By Topical (2021-2030) ($MN)
32 Global Retinal Disease Therapeutics Market Outlook, By Intravitreal (2021-2030) ($MN)
33 Global Retinal Disease Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
34 Global Retinal Disease Therapeutics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
35 Global Retinal Disease Therapeutics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
36 Global Retinal Disease Therapeutics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
37 Global Retinal Disease Therapeutics Market Outlook, By Direct Tender (2021-2030) ($MN)
38 Global Retinal Disease Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
39 Global Retinal Disease Therapeutics Market Outlook, By End User (2021-2030) ($MN)
40 Global Retinal Disease Therapeutics Market Outlook, By Hospitals (2021-2030) ($MN)
41 Global Retinal Disease Therapeutics Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
42 Global Retinal Disease Therapeutics Market Outlook, By Home Healthcare (2021-2030) ($MN)
43 Global Retinal Disease Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
